These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. [Liver and antitubercular drug therapy]. Viroglio AL; Piñeyro JO; Acosta A; Munaro N; Escarguel Malbrán J; Pérez JA Rev Fac Cienc Med Cordoba; 1974; 32(1):19-36. PubMed ID: 4458009 [No Abstract] [Full Text] [Related]
15. [Antitubercular drug-induced liver injuries]. Guo Y; Cui D Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960 [No Abstract] [Full Text] [Related]
16. Reply to Sharma et Al and Saukkonen et Al. Heller T; Wallrauch C; Lessells RJ Clin Infect Dis; 2010 Jul; 51(2):255. PubMed ID: 20560741 [No Abstract] [Full Text] [Related]
17. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909 [TBL] [Abstract][Full Text] [Related]
18. UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Chang JC; Liu EH; Lee CN; Lin YC; Yu MC; Bai KJ; Chen HY Int J Tuberc Lung Dis; 2012; 16(3):376-8. PubMed ID: 22230213 [TBL] [Abstract][Full Text] [Related]
19. Rifampin and pyrazinamide for treatment of latent tuberculosis infection. Cook PP Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576 [No Abstract] [Full Text] [Related]